![]() ![]() ![]() ![]() 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): MaEndo International UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): Endo International pl 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): Endo International p 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): JEndo International 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): AugEndo International 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): AugEndo Internationaįinancial Statements and Exhibits, Other Events 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): SeptemEndo Internatio All rights reserved This presentation containsĮNDO REPORTS THIRD-QUARTER 2021 FINANCIAL RESULTS AND RAISES 2021 FINANCIAL GUIDANCEĮNDO REPORTS SECOND-QUARTER 2021 FINANCIAL RESULTS AND UPDATES 2021 FINANCIAL GUIDANCEĮNDO REPORTS FIRST-QUARTER 2021 FINANCIAL RESULTS AND UPDATES 2021 FINANCIAL GUIDANCEĮndo International plc Announces Pricing of Private Offering Of Senior Secured NotesĮndo International plc Announces Proposed Private Offering Of Senior Secured NotesĮndo International plc Commences Refinancing of its Existing Term Loan Morgan Healthcare Conference Blaise Coleman, President & CEO ©2022 Endo International plc or one of its affiliates. ©2022 Endo International plc or one of its affiliates. Table of Contents 2022A Unaudited Results Feb 2023 Long Term Plan Feb 2023 Segment Projectionsĭisclaimer This document has been prepared by Endo International plc (“Endo” or the “Company”) and its advisors from information provided by Company management and other sources, and is subject in all respects to the confidentiality agreement you havĮndo to Cease Production and Sale of Qwo® (collagenase clostridium histolyticum-aaes)ĮNDO REPORTS THIRD-QUARTER 2022 FINANCIAL RESULTSĮndo International plc (Incorporated in Ireland with limited liability under the Companies Act 2014 with registered number 534814) Notice of Extraordinary General Meeting Convened Pursuant to Section 1111 of the Companies Act 2014Įndo Enters Into Restructuring Support Agreement with Senior Secured Debtholders to Strengthen Financial Position and Advance Ongoing Business Transformation Sale Transaction Would Result in a Substantial Reduction of Debt and Contemplates Purchaser-ĮNDO REPORTS SECOND-QUARTER 2022 FINANCIAL RESULTSĮNDO REPORTS FIRST-QUARTER 2022 FINANCIAL RESULTSĮndo Acquires Six Development-Stage, Ready-to-Use Injectable Product Candidates From NevakarĮNDO REPORTS FOURTH-QUARTER AND FULL-YEAR 2021 FINANCIAL RESULTS THIS DOCUMENT AND THE ACCOMPANYING FORM OF PROXY ARE IMPORTANT AND REQUIRE YOUR IMMEDIATE ATTENTION.ĮNDO REPORTS FIRST-QUARTER 2023 FINANCIAL RESULTSĮNDO REPORTS FOURTH-QUARTER 2022 FINANCIAL RESULTS ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |